Imaging methods for neuroendocrine tumors
Diagnosing pNETs requires a comprehensive approach using high-sensitivity imaging techniques.
- PET/CT. Recognized as the method of choice. The use of radiopharmaceuticals (68Ga-DOTATOC, 68Ga-DOTANOC, 68Ga-DOTATATE) provides maximum sensitivity and specificity. The method is indispensable for assessing extrapancreatic tumor burden and detecting small hypermetabolic foci (e.g., in MEN-1 syndrome) that are not visualized on standard MSCT.
- Magnetic resonance imaging (MRI). Sensitivity ranges from 63% to 94%. The most informative techniques are T1-weighted gradient echo images (T1 weighted GRE) with fat suppression, dynamic gadolinium-enhanced scanning, and diffusion-weighted imaging (DWI).
- Invasive diagnostics. To precisely localize the lesion in the head, body, or tail of the gland, selective arterial calcium stimulation with subsequent venous blood sampling is used.
When searching for small tumors (e.g., microinsulinomas up to 5 mm in size), adhering to contrast phases is critically important. On CT and MRI in the arterial phase, the lesion appears as a well-defined hypervascular focus, but in the venous phase, it may become isodense and very difficult to visualize.
Non-functioning pNETs: differential diagnosis
Non-functioning neuroendocrine tumors clinically mimic ductal adenocarcinoma, yet their treatment tactics differ fundamentally. It is important to remember that non-functioning pNETs are almost always malignant.
Key distinguishing CT features of non-functioning pNETs:
- Avid contrast enhancement. Intense contrast agent uptake is extremely uncharacteristic of adenocarcinoma, but is a typical marker for pNETs.
- Calcification. Found in approximately 22% of cases.
- Cystic transformation. Since up to 20% of pNETs have a partially cystic structure, they must be included in the differential diagnosis when pancreatic cysts are detected. On MRI, they appear as thick-walled hypervascular lesions.
Cystic lesions of the pancreas
For a long time, it was believed that 90% of fluid-filled lesions of the gland were post-inflammatory pseudocysts, but today this figure is recognized as overestimated. The proportion of true cystic neoplasms is steadily growing. About 90% of them belong to three histological types:
- Intraductal papillary mucinous neoplasms (IPMN). The most frequent type. They originate from the epithelium of the main pancreatic duct or side branches and produce mucin. The WHO classification distinguishes 4 stages: from dysplasia to invasive carcinoma.
- Mucinous cystadenoma. A macrocystic type lesion (cysts greater than 2 cm in diameter) with thin septa. Most of them eventually behave malignantly. The appearance of solid, contrast-enhancing nodules indicates transformation into mucinous cystadenocarcinoma. Therefore, the tumor requires surgical resection.
- Serous cystadenoma. Obsolete name: microcystic cystadenoma. Usually benign. Consists of numerous small cysts (less than 2 cm in diameter, most often more than six). A characteristic feature is a central scar or stellate calcification. If the microcysts are too small, the tumor may appear solid on CT, and MRI is required to confirm its fluid nature.
Principles of diagnostic verification
Precise characterization of cystic and solid lesions should be based on comparing clinical history and imaging data. For detailed visualization of structures (e.g., thin septa of mucinous cystadenoma), T2-weighted MRI images are preferred, while curved multiplanar reconstruction of CT images is used to detect lesions hidden within the parenchyma. When necessary, non-invasive data are supplemented with the results of fine-needle aspiration or core needle biopsy (core biopsy).
Briefly: answers to topical questions
What are the stages of intraductal papillary mucinous neoplasms (IPMN) according to the WHO classification?
According to the WHO classification, intraductal papillary mucinous neoplasms (IPMN) represent a wide spectrum of lesions ranging from benign to malignant and are subdivided into four categories.
The following stages are distinguished:
- Dysplasia (dysplasia) is the first category according to the WHO classification.
- Borderline tumors (borderline) is the second category.
- Carcinoma in situ (carcinoma in situ) is the third category.
- IPMN with invasive cancer (IPMN with invasive cancer) is the fourth category.
According to their location, these neoplasms are additionally divided into main duct type (main duct type), branch duct type (branch duct type), and mixed type (mixed type).
Which hereditary syndromes can be associated with pancreatic neuroendocrine tumors?
Pancreatic neuroendocrine tumors are associated with:
- Multiple endocrine neoplasia type 1 (MEN 1).
- Von Hippel–Lindau disease (von Hippel–Lindau disease).
What types of functioning pancreatic neuroendocrine tumors exist?
There are several types of functioning pancreatic neuroendocrine tumors that produce peptide hormones, leading to the development of characteristic clinical syndromes.
The following main types are distinguished:
- Insulinoma (Insulinoma) is the most common tumor causing episodes of hypoglycemia.
- Gastrinoma (Gastrinoma) produces gastrin, leading to Zollinger-Ellison syndrome.
- Glucagonoma (Glucagonoma) secretes glucagon.
- VIPoma (VIPoma) secretes vasoactive intestinal peptide.
- Somatostatinoma (Somatostatinoma) produces somatostatin.
- Serotonin-producing tumor secretes serotonin.
- ACTH-producing tumor secretes adrenocorticotropic hormone.
Serous cystadenoma is a microcystic tumor (many small cysts <2 cm). Mucinous cystadenoma is a macrocystic tumor (large cysts >2 cm) with a high risk of malignancy.
Class and exam questions
How to distinguish a non-functioning pNET from ductal adenocarcinoma on CT?
The main criterion is vascularization. A pNET intensely enhances in the arterial phase (is hypervascular) and becomes isodense in the venous phase. Ductal adenocarcinoma does not typically show strong contrast enhancement.
What is the main advantage of PET/CT in diagnosing pNETs?
PET/CT with somatostatin receptor radiopharmaceuticals (e.g., 68Ga-DOTATOC) allows for the detection of tiny hypermetabolic foci and extrapancreatic metastases that are not visible on standard MSCT.
Which imaging features indicate the malignant transformation of a mucinous cystadenoma?
Suspicion of mucinous cystadenoma arises when solid nodules that actively enhance with a contrast agent are detected within the cystic mass.
Why is serous cystadenoma sometimes mistakenly evaluated as a solid tumor on CT?
This occurs when the tumor consists of countless microscopic cysts that merge on a CT image. In such cases, MRI is used to reveal their true cystic nature.
What else to study on this topic
- Methodology for selective arterial calcium stimulation
- WHO histological classification for intraductal papillary mucinous neoplasms (IPMN)
- Imaging appearance of microinsulinomas in various contrast phases
- Features of applying curved multiplanar reconstruction in MSCT
Master the entire topic in the "Diagnostic Radiology" course
This is a summary. The course covers everything tested in classes and exams.
- Complete study guide on "Pancreatic neuroendocrine tumors" and 2,199 more pages of the subject
- Assignments and quizzes after every topic — just like in a colloquium
- AI tutor answers questions on the topic anytime
- 10 video lessons on the subject
Other topics in the section "Diagnostic Radiology of the Abdominal Organs"
Prepared by WhiteCoat Pro faculty in accordance with the medical school curriculum. For educational purposes only.